DeepMed Research

BeBetter Med Inc.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 3

Recruiting

Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Interventions: Drug: Ifupinostat Hydrochloride for Injection
Drug: Rituximab Injection
Drug: Gemcitabine Hydrochloride for Injection
Drug: Oxaliplatin Injection
Drug: Etoposide Injection
Drug: Ifosfamide for Injection
Drug: Carboplatin Injection

First Posted Date: 2025-01-24

Last Posted Date: 2025-01-24

Lead Sponsor: BeBetter Med Inc

Target Recruit Count: 416

Registration Number: NCT06792253

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Non-Small Cell Lung Cancer
EGFR Exon 20 Insertion Mutation

Interventions: Drug: BEBT-109 Capsule

First Posted Date: 2024-11-26

Last Posted Date: 2024-11-26

Lead Sponsor: BeBetter Med Inc

Target Recruit Count: 200

Registration Number: NCT06706713

Locations: 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer

Phase 2

Recruiting

Conditions: Advanced Triple-Negative Breast Cancer

Interventions: Drug: Carboplatin injection
Drug: BEBT-209 capsules
Drug: Gemcitabine hydrochloride for injection

First Posted Date: 2024-11-13

Last Posted Date: 2024-11-13

Lead Sponsor: BeBetter Med Inc

Target Recruit Count: 120

Registration Number: NCT06685796

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations

Phase 2

Not yet recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: BEBT-109 Capsules
Drug: Pemetrexed Disodium for Injection
Drug: Carboplatin Injection
Drug: Cisplatin Injection

First Posted Date: 2024-07-23

Last Posted Date: 2024-07-23

Lead Sponsor: BeBetter Med Inc

Target Recruit Count: 30

Registration Number: NCT06514027

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1

Recruiting

Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Interventions: Drug: BEBT-908 for Injection
Drug: Rituximab Injection
Drug: Gemcitabine Hydrochloride for Injection
Drug: Etoposide Injection
Drug: Ifosfamide for Injection
Drug: Oxaliplatin Injection
Drug: Carboplatin Injection

First Posted Date: 2023-12-11

Last Posted Date: 2023-12-11

Lead Sponsor: BeBetter Med Inc

Target Recruit Count: 75

Registration Number: NCT06164327

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Study of BEBT-607 Tablets in The Treatment of Advanced or Metastatic Solid Tumors With KRAS G12C Mutation

Phase 1

Recruiting

Conditions: KRAS G12C Mutation
Advanced or Metastatic Solid Tumor

Interventions: Drug: BEBT-607Tablets

First Posted Date: 2023-11-07

Last Posted Date: 2023-11-07

Lead Sponsor: BeBetter Med Inc

Target Recruit Count: 126

Registration Number: NCT06117371

Locations: 🇨🇳
Xiangya Hospital of Central South University, Changsha, Hunan, China

Study of BEBT-908 in Subjects With Advanced Hematological Tumors

Phase 1

Completed

Conditions: Relapsed or Refractory Multiple Myeloma
Relapsed or Refractory Non-Hodgkin's Lymphoma

Interventions: Drug: BEBT-908 for injection

First Posted Date: 2023-10-13

Last Posted Date: 2023-10-13

Lead Sponsor: BeBetter Med Inc

Target Recruit Count: 32

Registration Number: NCT06082596

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China

Study of BEBT-908 in the Relapsed or Refractory Diffuse Large B-cell Lymphoma Subjects

Phase 2

Active, not recruiting

Conditions: Relapsed or Refractory Diffuse Large B-cell Lymphoma

Interventions: Drug: BEBT-908 for injection

First Posted Date: 2023-10-10

Last Posted Date: 2023-10-11

Lead Sponsor: BeBetter Med Inc

Target Recruit Count: 128

Registration Number: NCT06074107

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China

Phase I Study of BEBT-209 in Women With Advanced Breast Cancer

Phase 1

Active, not recruiting

Conditions: Advanced Breast Cancer

Interventions: Drug: BEBT-209 capsules
Drug: Letrozole tablets
Drug: Fulvestrant

First Posted Date: 2023-09-21

Last Posted Date: 2023-09-21

Lead Sponsor: BeBetter Med Inc

Target Recruit Count: 106

Registration Number: NCT06047184

Locations: 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China

Study of Orally Administered BEBT-503 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: BEBT-503 20mg
Drug: placebo 20mg
Drug: BEBT-503 40mg
Drug: placebo 40mg
Drug: BEBT-503 80mg
Drug: placebo 80mg
Drug: BEBT-503 120mg
Drug: placebo 120mg
Drug: BEBT-503 180mg
Drug: placebo 180mg

First Posted Date: 2022-05-26

Last Posted Date: 2023-09-18

Lead Sponsor: BeBetter Med Inc

Target Recruit Count: 57

Registration Number: NCT05391880

Locations: 🇦🇺
Nucleus Network Pty Ltd, Melbourne, Australia

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy